{"id":4345,"date":"2020-05-15T08:20:13","date_gmt":"2020-05-15T06:20:13","guid":{"rendered":"http:\/\/us-patente.com.www243.your-server.de\/?page_id=4345"},"modified":"2022-09-02T16:43:39","modified_gmt":"2022-09-02T14:43:39","slug":"legal-publications","status":"publish","type":"page","link":"https:\/\/us-patente.com\/en\/attorneys\/dr-siegfried-j-w-ruppert\/legal-publications\/","title":{"rendered":"Legal Publications"},"content":{"rendered":"<div class=\"container-fluid\"><div class=\"container\"><div id=\"element_1177609935186\" class=\"el_row row\"><div class=\"inner-row\"><div id=\"element_2\" class=\"el_column col-md-12\"><div class=\"inner-column\"><div id=\"element-3\" class=\"section-head left layout-petro\"><div><h2 class=\"section-main-title\">Dipl.-Biol. Siegfried J.W. Ruppert<\/h2><\/div><\/div><div id=\"element_4177609935142\" class=\"el_text\"><h4>U.S. Attorney | U.S. Patent Attorney<\/h4><\/div><div id=\"element_5177609935164\" class=\"el_text\"><h3 style=\"color: #c7b29a;\">Legal Publications<\/h3>\n<p>As author and co-author with his U.S. attorney colleagues, on the topics of biosimilars and patentability of biological molecules and diagnostic methods, Dr. Ruppert has published the legal papers listed below:<\/p>\n<ul>\n<li>Co-Author, &#8220;<a href=\"https:\/\/www.mondaq.com\/unitedstates\/Food-Drugs-Healthcare-Life-Sciences\/297368\/The-USPTO-Issues-Its-Myriad-Guidance-aka-What-Is-Enough\"><em>The USPTO Issues Its \u201cMyriad\u201d Guidance \u2013 a.k.a. What is \u201cEnough\u201d<\/em><\/a>,\u201d Duane Morris Alert, March 04, 2014, Republished <em>Mondaq<\/em>, March 05, 2014.<\/li>\n<li>Co-Author, &#8220;<a href=\"https:\/\/www.mondaq.com\/unitedstates\/Food-Drugs-Healthcare-Life-Sciences\/231752\/Virginia-Enacts-The-First-State-Law-Regulating-Interchangeable-Biosimilar-Products\"><em>Virginia Enacts The First State Law Regulating Interchangeable Biosimilar Products<\/em><\/a>,&#8221; Duane Morris Alert, March 28, 2013.<\/li>\n<li>Co-Author, &#8220;<a href=\"https:\/\/mondaq.com\/unitedstates\/Food-Drugs-Healthcare-Life-Sciences\/168794\/Path-For-Generic-Competition-Open-In-Biotechnology-Industry\"><em>Path for Generics Open in Biotech<\/em><\/a>,&#8221; <em>The Recorder<\/em>, March 05, 2012; Republished <em>Mondaq<\/em>, March 15, 2012<\/li>\n<li>Co-Author, &#8220;<a href=\"https:\/\/www.duanemorris.com\/articles\/static\/norton_ruppert_genericsweb_0212.pdf\"><em>FDA&#8217;s Draft Guidance on \u2018Biosimilar\u2019 Pathway Leaves Key Questions on Specific Clinical Data Requirements and Interchangeability Unanswered<\/em><\/a>,&#8221; GenericsWeb Newsletter <em>InnSight<\/em>, February 2012<\/li>\n<li>Co-Author, &#8220;<a href=\"https:\/\/www.duanemorris.com\/alerts\/FDA_draft_guidances_implement_biologics_price_competition_innovation_act_4355.html\"><em>FDA Issues Draft Guidance Documents to Implement the Biologics Price Competition and Innovation Act of 2009<\/em><\/a>,&#8221; Duane Morris Alert, February 13, 2012.<\/li>\n<li>Author, &#8220;<a href=\"https:\/\/www.duanemorris.com\/alerts\/FDA_sends_prescription_drug_user_fee_act_v_to_congress_for_reauthorization_4339.html\"><em>FDA Sends Prescription Drug User Fee Act V to Congress for Reauthorization<\/em><\/a>,&#8221; Duane Morris Alert, January 23, 2012.<\/li>\n<li>Co-Author, &#8220;<em>Forecasting Forthcoming &#8216;Biosimilar&#8217; Drug Regulations<\/em>,&#8221; <em>The Recorder<\/em>, 30. August 2011.<\/li>\n<li>Author, &#8220;<a href=\"https:\/\/www.mondaq.com\/unitedstates\/life-sciences-biotechnology-nanotechnology\/144830\/a-look-ahead-fdas-approach-to-biosimilars-totality-of-the-evidence-and-riskbased\"><em>A Look Ahead: FDA\u2019s Approach to Biosimilars &#8211; Totality of the Evidence and Risk-Based<\/em><\/a>,&#8221; GenericsWeb newsletter<em> InnSight<\/em>, August 2011, Republished Mondaq, 08. September 2011<\/li>\n<li>Author, &#8220;<a href=\"https:\/\/www.mondaq.com\/unitedstates\/patents\/130292\/biosimilars--faster-development-and-approval\"><em>Biosimilars &#8211; Faster Development and Approval?,<\/em><\/a>&#8221; GenericsWeb newsletter <em>InnSight<\/em>, M\u00e4rz 2011, Republished <em>Mondaq<\/em>, 26. April 2011.<\/li>\n<\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":4283,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/pages\/4345"}],"collection":[{"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/comments?post=4345"}],"version-history":[{"count":9,"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/pages\/4345\/revisions"}],"predecessor-version":[{"id":4752,"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/pages\/4345\/revisions\/4752"}],"up":[{"embeddable":true,"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/pages\/4283"}],"wp:attachment":[{"href":"https:\/\/us-patente.com\/en\/wp-json\/wp\/v2\/media?parent=4345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}